Сравнение
Amycretin vs. Cagrilintide
Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.
Идентичность
Категория
Метаболизм
Метаболизм
Номер CAS
нет данных
1415456-99-3
Молекулярная масса
нет данных
4253.7 g/mol
Период полувыведения
нет данных
168 h
Последовательность
нет данных
KCNTATCATQRLANFLVRSSNNLGPVLPPTNVGSNTYМеханизм действия
Amycretin
Amycretin activates both the GLP-1 and the amylin receptor in a single molecule. Both pathways independently suppress appetite and food intake — the combination is intended to amplify the effect beyond the GLP-1 axis alone.
Cagrilintide
Cagrilintide binds amylin receptors (AMY1, AMY3, formed by the calcitonin receptor plus RAMP proteins). Activation delays gastric emptying, inhibits postprandial glucagon secretion and modulates central satiety signalling via area postrema neurons. An acyl modification enables albumin binding and thereby weekly dosing.
Доказательная база
Наивысшая доказательность
РКИ на людях
РКИ на людях
Исследования
1
4
из них на людях
1
3
Зафиксированные эффекты
2
3
Открытые противоречия
0
1
Задокументированные нежелательные явления
1
1
Правовой статус
Полные записи
Frequently asked questions
- What is the difference between Amycretin and Cagrilintide?
- Amycretin is classified as "Метаболизм", while Cagrilintide is classified as "Метаболизм". Amycretin: Amycretin is a unimolecular GLP-1 and amylin receptor agonist from Novo Nordisk — in development both as a once-weekly subcutaneous and a once-daily oral form for obesity and type 2 diabetes. Cagrilintide: Synthetic long-acting amylin analog being developed in combination with semaglutide (CagriSema). Phase 3 trials for obesity and type 2 diabetes are ongoing. No marketing approval yet. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Amycretin or Cagrilintide?
- The highest available evidence level is "РКИ на людях" for Amycretin and "РКИ на людях" for Cagrilintide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Amycretin and Cagrilintide in Germany and the United States?
- Германия: Amycretin — Не одобрено, Cagrilintide — Не одобрено. США: Amycretin — Не одобрено, Cagrilintide — Не одобрено. These are factual summaries with source and review date on the individual pages.